Skip to main content
TipRanks
Go Ultimate75% OFF

Compare GlaxoSmithKline (GS71) vs. Competitors

0 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
CH:GS71GlaxoSmithKlineCHF 26.12CHF 80.52B17.060.00%HoldUnlock the CH:GS71 analyst price target with TipRanks PremiumCH:GS71Unlock the CH:GS71 top-analyst price target with TipRanks Premium
GB:AZNAstraZenecaGBX 13,412.00GBX 206.33B24.64-1.74%Strong BuyUnlock the GB:AZN analyst price target with TipRanks PremiumCH:GS71 vs GB:AZNUnlock the GB:AZN top-analyst price target with TipRanks Premium
GB:HIKHikma PharmaceuticalsGBX 1,686.00GBX 3.49B12.327.80%Strong BuyUnlock the GB:HIK analyst price target with TipRanks PremiumCH:GS71 vs GB:HIKUnlock the GB:HIK top-analyst price target with TipRanks Premium
GB:SNSmith & NephewGBX 1,145.00GBX 9.49B19.71-6.99%HoldUnlock the GB:SN analyst price target with TipRanks PremiumCH:GS71 vs GB:SNUnlock the GB:SN top-analyst price target with TipRanks Premium
GB:BXPBeximco Pharmaceuticals Limited Sponsored GDR RegSGBX 57.50GBX 66.65B4.4341.98%―Unlock the GB:BXP analyst price target with TipRanks PremiumCH:GS71 vs GB:BXPUnlock the GB:BXP top-analyst price target with TipRanks Premium
GB:HLNHaleon PLCGBX 345.30GBX 29.98B19.04-6.57%Moderate BuyUnlock the GB:HLN analyst price target with TipRanks PremiumCH:GS71 vs GB:HLNUnlock the GB:HLN top-analyst price target with TipRanks Premium

Performance Comparison

-40%-20%0%20%40%60%80%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
CH:GS71GlaxoSmithKline26.110.000.00%
GB:AZNAstraZeneca13412.00-175.83-1.29%
GB:HIKHikma Pharmaceuticals1686.00162.0810.64%
GB:SNSmith & Nephew1145.00-73.18-6.01%
GB:BXPBeximco Pharmaceuticals Limited Sponsored GDR RegS57.5020.2954.52%
GB:HLNHaleon PLC345.30-24.41-6.60%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts